Royal Philips has announced that its groundbreaking navigation system LumiGuide 3D Device Guidance, which is now commercially available across Europe and the United States, marking a major milestone in the adoption of radiation-free image-guided therapy.
LumiGuide is the world’s first real-time, AI-enabled, light-based 3D navigation system for image-guided therapy. Unlike traditional methods that rely on continuous X-ray imaging, LumiGuide uses an optical fiber embedded in a guidewire to reflect light, allowing physicians to visualize the shape and position of guidewires and compatible catheters inside the body in full-color, high-resolution 3D in real time.
The system integrates into Philips’ existing image-guided therapy platform Azurion, leveraging an established infrastructure used by medical facilities worldwide.
The move to a broader rollout follows a limited market release in late 2023, during which the system was tested at select aortic-centres.
LumiGuide can substantially improve procedural efficiency and safety. Complex procedures such as aortic repairs have been carried out up to 37 percent faster when using LumiGuide, and with reductions in radiation exposure (as measured by Dose-Area Product, or DAP) reaching up to 56 percent.
Philips positions LumiGuide as part of a larger strategy to reduce reliance on ionizing radiation during minimally invasive interventions. By combining AI-enabled guidance, real-time 3D visualisation, and integration with established therapy platforms, the company aims to bring greater precision, efficiency and safety to endovascular and other interventional procedures worldwide.
